HomeCompareGBS vs ORCC

GBS vs ORCC: Dividend Comparison 2026

GBS yields 422.65% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBS wins by $17170.29M in total portfolio value
10 years
GBS
GBS
● Live price
422.65%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17170.31M
Annual income
$11,716,925,996.02
Full GBS calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — GBS vs ORCC

📍 GBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBSORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBS + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBS pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBS
Annual income on $10K today (after 15% tax)
$35,925.61/yr
After 10yr DRIP, annual income (after tax)
$9,959,387,096.62/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, GBS beats the other by $9,959,387,095.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBS + ORCC for your $10,000?

GBS: 50%ORCC: 50%
100% ORCC50/50100% GBS
Portfolio after 10yr
$8585.17M
Annual income
$5,858,462,998.53/yr
Blended yield
68.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

GBS
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-6.8
Piotroski
5/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBS buys
0
ORCC buys
0
No recent congressional trades found for GBS or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBSORCC
Forward yield422.65%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$17170.31M$21.4K
Annual income after 10y$11,716,925,996.02$1.04
Total dividends collected$16675.91M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: GBS vs ORCC ($10,000, DRIP)

YearGBS PortfolioGBS Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$52,965$42,265.43$11,190$489.61+$41.8KGBS
2$265,889$209,215.55$12,229$256.01+$253.7KGBS
3$1,266,062$981,561.13$13,216$130.74+$1.25MGBS
4$5,722,749$4,368,062.66$14,207$66.02+$5.71MGBS
5$24,575,825$18,452,483.99$15,234$33.17+$24.56MGBS
6$100,354,560$74,058,426.77$16,317$16.62+$100.34MGBS
7$390,010,320$282,630,940.68$17,468$8.32+$389.99MGBS
8$1,443,848,768$1,026,537,725.78$18,695$4.16+$1443.83MGBS
9$5,096,622,021$3,551,703,839.84$20,006$2.08+$5096.60MGBS
10$17,170,311,559$11,716,925,996.02$21,407$1.04+$17170.29MGBS

GBS vs ORCC: Complete Analysis 2026

GBSStock

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Full GBS Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this GBS vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBS vs SCHDGBS vs JEPIGBS vs OGBS vs KOGBS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.